Literature DB >> 33451065

A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration.

Giovanni Ribaudo1, Maurizio Memo1, Alessandra Gianoncelli1.   

Abstract

As life expectancy increases, dementia affects a growing number of people worldwide. Besides current treatments, phosphodiesterase 9 (PDE9) represents an alternative target for developing innovative small molecules to contrast neurodegeneration. PDE inhibition promotes neurotransmitter release, amelioration of microvascular dysfunction, and neuronal plasticity. This review will provide an update on natural and nature-inspired PDE9 inhibitors, with a focus on the structural features of PDE9 that encourage the development of isoform-selective ligands. The expression in the brain, the presence within its structure of a peculiar accessory pocket, the asymmetry between the two subunits composing the protein dimer, and the selectivity towards chiral species make PDE9 a suitable target to develop specific inhibitors. Additionally, the world of natural compounds is an ideal source for identifying novel, possibly asymmetric, scaffolds, and xanthines, flavonoids, neolignans, and their derivatives are currently being studied. In this review, the available literature data were interpreted and clarified, from a structural point of view, taking advantage of molecular modeling: 3D structures of ligand-target complexes were retrieved, or built, and discussed.

Entities:  

Keywords:  Alzheimer’s disease; PDE9; cGMP; natural compounds; neurodegeneration; xanthines

Year:  2021        PMID: 33451065      PMCID: PMC7828511          DOI: 10.3390/ph14010058

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  59 in total

Review 1.  A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs.

Authors:  Roja Rahimi; Sima Ghiasi; Hanieh Azimi; Sima Fakhari; Mohammad Abdollahi
Journal:  Cytokine       Date:  2009-12-14       Impact factor: 3.861

2.  Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin.

Authors:  Francisco Orallo; Mercedes Camiña; Ezequiel Alvarez; Hélène Basaran; Claire Lugnier
Journal:  Planta Med       Date:  2005-02       Impact factor: 3.352

Review 3.  Phosphodiesterase inhibition in cognitive decline.

Authors:  Carolina García-Barroso; Ana Ugarte; Martín Martínez; Alberto J Rico; José Luis Lanciego; Rafael Franco; Julen Oyarzabal; Mar Cuadrado-Tejedor; Ana García-Osta
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.

Authors:  P H Hutson; E N Finger; B C Magliaro; S M Smith; A Converso; P E Sanderson; D Mullins; L A Hyde; B K Eschle; Z Turnbull; H Sloan; M Guzzi; X Zhang; A Wang; D Rindgen; R Mazzola; J A Vivian; D Eddins; J M Uslaner; R Bednar; C Gambone; W Le-Mair; M J Marino; N Sachs; G Xu; S Parmentier-Batteur
Journal:  Neuropharmacology       Date:  2011-05-19       Impact factor: 5.250

5.  Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.

Authors:  C Lugnier; V B Schini
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

6.  Screening for phosphodiesterase inhibitory activity of Thai medicinal plants.

Authors:  Prapapan Temkitthawon; Jarupa Viyoch; Nanteetip Limpeanchob; Wittaya Pongamornkul; Chawlada Sirikul; Anchana Kumpila; Khanit Suwanborirux; Kornkanok Ingkaninan
Journal:  J Ethnopharmacol       Date:  2008-06-06       Impact factor: 4.360

7.  The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue.

Authors:  Roberta L Gonçalves; Claire Lugnier; Thérèse Keravis; Miguel J Lopes; Fernando A Fantini; Martine Schmitt; Steyner F Cortes; Virginia S Lemos
Journal:  Eur J Pharmacol       Date:  2009-08-15       Impact factor: 4.432

Review 8.  Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.

Authors:  Francis T Hane; Morgan Robinson; Brenda Y Lee; Owen Bai; Zoya Leonenko; Mitchell S Albert
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.

Authors:  Chen Zhang; Qian Zhou; Xu-Nian Wu; Ya-Dan Huang; Jie Zhou; Zengwei Lai; Yinuo Wu; Hai-Bin Luo
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

View more
  1 in total

1.  Anti-Inflammatory Effects of Psoralen Derivatives on RAW264.7 Cells via Regulation of the NF-κB and MAPK Signaling Pathways.

Authors:  Yeji Lee; Chang-Gu Hyun
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.